Cocaine Use Disorder Market Size Poised for Transformation Through 2034

The Cocaine Use Disorder market size was valued at approximately USD 48.6 million in 2023 and is expected to witness notable growth, registering a significant CAGR during the forecast period from 2020 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Cocaine Use Disorder landscape.

Several prominent companies, including STALICLA and Embera NeuroTherapeutics, along with other emerging players, are contributing to the development of the Cocaine Use Disorder market landscape. Comprehensive details regarding the market size by country and by therapy are outlined in the sections below.

In 2023, the United States generated approximately USD 30 million in the cocaine use disorder market. Within the total market size across the 7MM, the United States held the largest share, accounting for over 55% in 2023, followed by Germany and the United Kingdom. Among the EU4 and the UK, Germany represented nearly 25% of the cocaine use disorder market size in 2023.

According to an analysis by DelveInsight, the total number of diagnosed prevalent cases of cocaine use disorder (CUD) across the 7MM over a 12-month period was estimated at approximately 1,880,064 in 2023. This patient population is expected to increase by 2034, registering a notable compound annual growth rate during the forecast period from 2020 to 2034.

In 2023, approximately 429,731 cases of cocaine use disorder (CUD) were reported among males in the EU4 and the UK, while the number of cases among females was around 187,167. These figures are projected to increase by 2034. In the same year, Japan recorded nearly 61,200 mild cases and about 40,630 moderate to severe cases of CUD, and these numbers are expected to change over the forecast period through 2034. According to assessments by DelveInsight, the United States reported approximately 1,161,337 diagnosed prevalent cases of CUD in 2023, with the patient population anticipated to grow further by 2034.

DelveInsight’s report, “Cocaine Use Disorder Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Cocaine Use Disorder landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Cocaine Use Disorder market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Cocaine Use Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cocaine Use Disorder Market Forecast

Some of the key facts of the Cocaine Use Disorder Market Report:

• Currently, only Standard of Care (SOC) is being used as the only option of therapy for the Cocaine Use Disorder Treatment.
• Key Cocaine Use Disorder Companies: STALICLA, Novartis, Embera NeuroTherapeutics, Tonix Pharmaceuticals, and others
• Key Cocaine Use Disorder Therapies: Mavoglurant (STP7), EMB-001, TNX-1300 (Injection), and others
• The Cocaine Use Disorder market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cocaine Use Disorder pipeline products will significantly revolutionize the Cocaine Use Disorder market dynamics.

Cocaine Use Disorder Overview

Cocaine Use Disorder is a chronic medical condition characterized by the compulsive use of cocaine despite its harmful physical, psychological, and social effects. It is classified as a substance use disorder and can lead to dependence, tolerance, and withdrawal symptoms when the drug is not used.

Cocaine Use Disorder is associated with serious health risks, including cardiovascular complications, neurological damage, mental health disorders, and an increased risk of overdose. The disorder often co-occurs with other substance use or psychiatric conditions, making management more complex.

Treatment for cocaine use disorder typically involves a combination of behavioral therapies, counseling, rehabilitation programs, and, in some cases, investigational pharmacological interventions aimed at reducing cravings, preventing relapse, and supporting long-term recovery. Early diagnosis and intervention are crucial for improving patient outcomes and reducing the social and healthcare burden of Cocaine Use Disorder.

Get a Free sample for the Cocaine Use Disorder Market Report -

https://www.delveinsight.com/report-store/cocaine-use-disorder-market

Key Trends in Cocaine Use Disorder Therapeutics Market:

• High Unmet Need for Approved Pharmacotherapies: One of the major trends in the cocaine use disorder therapeutics market is the significant unmet medical need due to the absence of FDA-approved medications specifically for cocaine addiction. This gap is driving extensive research and creating opportunities for pharmaceutical companies to develop novel pharmacological therapies.
• Expansion of Clinical Pipeline and Emerging Therapies: The therapeutic pipeline for cocaine use disorder is gradually expanding with investigational drugs targeting neurotransmitter pathways, craving reduction, and relapse prevention. Increased clinical research activity reflects growing interest from biotechnology and pharmaceutical companies in addressing this underserved therapeutic area.
• Growing Adoption of Digital Health and Telepsychiatry: Digital therapeutics, telepsychiatry platforms, and mobile health applications are becoming increasingly important in addiction management. These technologies enable remote counseling, continuous monitoring, and improved patient engagement, expanding access to treatment for individuals with cocaine use disorder.
• Development of Novel Therapeutic Approaches: Researchers are exploring innovative treatment strategies such as long-acting injectable therapies, monoclonal antibodies, and anti-cocaine vaccines to reduce cravings and prevent relapse. These emerging approaches represent a shift toward more targeted and mechanism-based addiction therapies.
• Increasing Awareness and Government Support for Addiction Treatment: Governments and healthcare organizations are expanding addiction treatment programs, awareness campaigns, and harm-reduction initiatives. These efforts are improving early diagnosis and encouraging more individuals to seek treatment, thereby supporting the growth of the cocaine use disorder therapeutics market.

Cocaine Use Disorder Epidemiology

The Cocaine Use epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cocaine Use Disorder Epidemiology Segmentation:

The Cocaine Use Disorder market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Cocaine Use Disorder
• Prevalent Cases of Cocaine Use Disorder by severity
• Gender-specific Prevalence of Cocaine Use Disorder
• Diagnosed Cases of Episodic and Chronic Cocaine Use Disorder

Download the report to understand which factors are driving Cocaine Use Disorder epidemiology trends @ Cocaine Use Disorder Epidemiology Forecast

Recent Development In The Cocaine Use Disorder Treatment Landscape:

• In October 2024, ANANDA Scientific Inc., a biopharmaceutical company focused on research, has announced the start of a clinical trial to evaluate Nantheia™ ATL5, an investigational drug that combines cannabidiol (CBD) with delta-9-tetrahydrocannabinol (THC). The drug utilizes ANANDA's proprietary delivery technology and is being tested for its potential effectiveness in treating co-occurring opioid use disorder (OUD) and chronic pain. (Clinical Trials.gov Identifier: NCT06544291)

Cocaine Use Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cocaine Use Disorder market or expected to get launched during the study period. The analysis covers Cocaine Use Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cocaine Use Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cocaine Use Disorder Therapies and Key Companies

• Mavoglurant (STP7): STALICLA/Novartis
• EMB-001: Embera NeuroTherapeutics
• TNX-1300 (Injection): Tonix Pharmaceuticals

Discover more about therapies set to grab major Cocaine Use Disorder market share @ Cocaine Use Disorder Treatment Market

Cocaine Use Disorder Market Drivers

• Rising Prevalence of Cocaine Use and Addiction: The increasing number of individuals affected by cocaine use disorder globally is a key factor driving market growth. Growing substance abuse trends and the high risk of dependency are increasing the demand for effective treatment and rehabilitation solutions.
• Increasing Awareness and Government Initiatives: Governments and public health organizations are implementing programs to combat substance abuse, including awareness campaigns, harm-reduction strategies, and expanded access to addiction treatment services.
• Growing Research and Clinical Development Activities: Pharmaceutical and biotechnology companies are investing in research to develop novel pharmacological treatments and behavioral therapies for cocaine addiction, leading to a growing therapeutic pipeline.
• Advancements in Digital Health and Behavioral Therapies: The integration of digital therapeutics, telemedicine platforms, and mobile health applications in addiction treatment is improving patient monitoring, counseling access, and overall treatment outcomes.
• Expansion of Rehabilitation and Addiction Treatment Centers: The increasing number of specialized rehabilitation centers and outpatient treatment programs is improving access to care and supporting the growth of the cocaine use disorder treatment market.

Cocaine Use Disorder Market Barriers

• Lack of Approved Pharmacological Treatments: One of the major challenges in the cocaine use disorder market is the limited availability of FDA-approved medications specifically designed to treat cocaine addiction.
• High Relapse Rates Among Patients: Substance use disorders, including cocaine addiction, often have high relapse rates, which can complicate long-term treatment success and limit the effectiveness of available therapies.
• Social Stigma Associated with Substance Abuse: Stigma surrounding addiction may discourage individuals from seeking treatment, leading to underdiagnosis and reduced participation in treatment programs.
• Limited Access to Treatment in Developing Regions: In many low- and middle-income countries, limited healthcare infrastructure and inadequate addiction treatment facilities restrict access to effective treatment options.
• Regulatory and Clinical Development Challenges: Developing new drugs for addiction treatment involves complex clinical trials, regulatory scrutiny, and high development costs, which can slow the introduction of new therapies to the market.

Scope of the Cocaine Use Disorder Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Cocaine Use Disorder Companies: STALICLA, Novartis, Embera NeuroTherapeutics, Tonix Pharmaceuticals, and others
• Key Cocaine Use Disorder Therapies: Mavoglurant (STP7), EMB-001, TNX-1300 (Injection), and others
  Cocaine Use Disorder Therapeutic Assessment: Cocaine Use Disorder current marketed and Cocaine Use Disorder emerging therapies
• Cocaine Use Disorder Market Dynamics: Cocaine Use Disorder market drivers and Cocaine Use Disorder market barriers 
• Cocaine Use Disorder Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Cocaine Use Disorder Unmet Needs, KOL’s views, Analyst’s views, Cocaine Use Disorder Market Access and Reimbursement 

To know more about Cocaine Use Disorder companies working in the treatment market, visit @ Cocaine Use Disorder Clinical Trials and Therapeutic Assessment

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.